Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate, Palombo-Kinne E, Schellschmidt I, Gräser T. Contraception 2009; 79: 282—289

A recent Cochrane Review found that combined oral contraceptives (COCs) reduced acne lesion counts, severity grades and self-assessed acne compared to placebo. However, differences in the effectiveness of COCs with varying progesterin types and dosages were less clear.

Ethinylestradiol (EE) and cyproterone acetate (CPA) is used as a hormonal treatment for acne, due to its anti-androgenic action. The British National Formulary (BNF) states that it can be a useful treatment option for women who also require oral contraception.

The authors of this study report on a drug company-funded, randomised, double-blind, three-arm study that recruited healthy women aged 16—45 years with mild to moderate facial acne from 65 centres in eastern Europe and the Russian Federation. Their aim was to determine whether a COC-containing dienogest (DNG) was non-inferior to placebo and non-inferior to EE/CPA in the treatment of mild to moderate acne.

Participants were allocated to six cycles of treatment (EE/2 mg CPA or (530), 0.035 mg EE/2 mg CPA (n = 541) or placebo (n = 267)). Primary outcome measures were the percentage change of inflammatory and total lesion counts, and the percentage of patients with improvements according to the Investigator Global Assessment.

The authors state that all primary analyses prove that EE/DNG was superior to placebo and non-inferior to EE/CPA (p<0.05). For total lesion count the percentage change (±SD) from baseline to cycle six was: −54.7 ± 26.3% (n = 515) for EE/DNG, −53.6 ± 27.5% (n = 528) for EE/CPA and −39.4 ± 33.6% (n = 259) for placebo.

Points to note include the fact that this study was concerned with treatment of mild to moderate acne, whereas the BNF states that EE/CPA is licensed for women with severe acne not responding to oral antibacterial treatment. In addition, the primary analysis to treat analysis was not used. Although a statistically significant (p<0.05) difference was found between the means of all three primary outcome measures of the BNF, the percentage effective was lower and non-inferiority of EE/DNG, given the large placebo effect it is unclear whether this equates with a clinically significant difference.

Reviewed by Bruno Rushforth, MBChB, DFSRH
General Practice Specialty Registrar, Outwood Park Medical Centre, Wakefield, UK
Reference


Presently the treatment regimen for termination of early pregnancy (less than 63 days gestation) in the UK comprises 200 mg mifepristone orally followed by 800 μg misoprostol vaginally 36—48 hours later. Although unlicensed, these are the guidelines from the Royal College of Obstetricians and Gynaecologists (2004) for regimens for inducing medical abortion. The mifepristone works to soften and dilate the uterine cervix and sensitise the myometrium prior to uterine contractility and adjuvant misoprostol. Pharmacokinetic studies suggest that oral administration of 100 mg or higher single doses of mifepristone result in similarly efficacious serum concentrations. Data available regarding the clinical efficacy of these treatments suggest that the efficacy is highest when the interval is 48 hours. No research studies previously have investigated the time between doses, or the comparison of 100 mg with 200 mg mifepristone.

This study had four treatment arms (mifepristone 100 mg orally followed by 800 μg misoprostol vaginally either 24 or 48 hours subsequently, and mifepristone 200 mg followed by 800 μg misoprostol after 24 or 48 hours) to which 2126 women were randomised, across 13 obstetric and gynaecology departments in nine countries. Through a thorough selection protocol almost equal numbers (with significant similarities in age and weight, premenstrual data and previous terminations) were recruited to each arm across all sites; randomisation was achieved by utilisation of an international sequence produced by the World Health Organization in Geneva.

The double-blind, placebo-controlled, randomised and powered with a low attrition rate (55 from 2181 women). Even those patients who lost follow-up are counted as failures of method when in fact they may have had complete abortions. Internal validity was achieved by randomisation and a required confidence interval of 95% for the difference in complete abortion rates – the margin of equivalence of 5% having been chosen by the research ethics committee judgement. External validity was demonstrated as women were enrolled from several different populations and included clinicians with different levels of experience of medical abortions.

The primary outcome measure was efficacy of the treatment in inducing complete abortion in all arms. The study found that both doses and all administration intervals are equivalent when taken. The results were inconclusive when the gestational age is 50 days or more. The findings show similar efficacy for complete abortion with both mifepristone doses and both treatment intervals. Despite the higher risk of mifepristone administration previously being demonstrated at 36—48 hours before the prostaglandin analogue use, this study found the 24-hour interval to have lower failure rates than the 48-hour interval group. Also both mifepristone doses produced equivalent rates of failure to achieve complete abortion within each interval of misoprostol administration. Reports of side effects were lower in the 24-hour interval group, suggesting this regimen could be better tolerated and provide a more pleasant patient experience. Overall conclusions are that the dose of mifepristone could be lowered to 100 mg and the administration interval between that and 800 μg misoprostol could be shortened to 24 hours without detrimental effect when terminating early pregnancy. This could have many repercussions in termination service including reducing cost implications of higher doses and the provision of well-tolerated regimens.

Reviewed by Rebecca Pullen, BSc, LLM
Nurse Consultant in Sexual Health (Contraceptive Health), Lincolshire Community Health Services, Lincolnshire, UK

Adverse events should be reported. Reporting forms and information can be found at www.youcanlook.org. Adverse events should also be reported to Bayer Schering Pharma, Bayer plc, Bayer House, Strawberry Hill, Newbury, Berkshire RG1 4LA 1.4 UK. Telephone: 01635 635600. Date of production May 2009 © = Qlaira is a registered trademark of Bayer Schering Pharma AG.
Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg Dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate

Bruno Rushforth

J Fam Plann Reprod Health Care 2009 35: 150
doi: 10.1783/147118909788707968

Updated information and services can be found at:
http://jfprhc.bmj.com/content/35/3/150.1.citation

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/